BTIG Maintains Sell on Ginkgo Bioworks Holdings, Adjusts Price Target To $7 (1-40 Reverse Stock Split)
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Mark Massaro maintains a Sell rating on Ginkgo Bioworks Holdings (NYSE:DNA) and adjusts the price target to $7 following a 1-40 reverse stock split.
August 23, 2024 | 5:17 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
BTIG analyst Mark Massaro maintains a Sell rating on Ginkgo Bioworks Holdings and adjusts the price target to $7 due to a 1-40 reverse stock split.
The maintenance of a Sell rating by BTIG and the adjustment of the price target to $7 following a reverse stock split suggests a negative outlook on Ginkgo Bioworks' stock performance. The reverse split may indicate attempts to boost the stock price, but the Sell rating implies skepticism about future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100